Jim Leng
YOU?
Author Swipe
View article: Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort
Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort Open
High-burden ICP was associated with decreased OS and neurologic decline. Patients who had oligometastatic disease, who received post-SRS immunotherapy, who did not receive pre-SRS immunotherapy, and who had a single BM had improved freedom…
View article: POSS: Position Specialist Generates Better Draft for Speculative Decoding
POSS: Position Specialist Generates Better Draft for Speculative Decoding Open
Speculative decoding accelerates Large Language Model (LLM) inference by using a small draft model to predict multiple tokens, and a large target model to verify these tokens in parallel. Recent studies leverage the hidden state of the tar…
View article: Multi-institutional Outcomes after Stereotactic Radiosurgery for Gastrointestinal Brain Metastases
Multi-institutional Outcomes after Stereotactic Radiosurgery for Gastrointestinal Brain Metastases Open
Across a multi-institutional stereotactic radiosurgery cohort, brain metastases of gastrointestinal origin demonstrated inferior overall survival and intracranial progression-free survival to those of nongastrointestinal origin. These data…
View article: CrossWordBench: Evaluating the Reasoning Capabilities of LLMs and LVLMs with Controllable Puzzle Generation
CrossWordBench: Evaluating the Reasoning Capabilities of LLMs and LVLMs with Controllable Puzzle Generation Open
Existing reasoning evaluation frameworks for Large Language Models (LLMs) and Large Vision-Language Models (LVLMs) predominantly assess either text-based reasoning or vision-language understanding capabilities, with limited dynamic interpl…
View article: Efficient Test-Time Scaling via Self-Calibration
Efficient Test-Time Scaling via Self-Calibration Open
Increasing test-time computation is a straightforward approach to enhancing the quality of responses in Large Language Models (LLMs). While Best-of-N sampling and Self-Consistency with majority voting are simple and effective, they require…
View article: Targeting glycolysis: exploring a new frontier in glioblastoma therapy
Targeting glycolysis: exploring a new frontier in glioblastoma therapy Open
Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgica…
View article: Taming Overconfidence in LLMs: Reward Calibration in RLHF
Taming Overconfidence in LLMs: Reward Calibration in RLHF Open
Language model calibration refers to the alignment between the confidence of the model and the actual performance of its responses. While previous studies point out the overconfidence phenomenon in Large Language Models (LLMs) and show tha…
View article: MMOD-05 THE IMPACT OF EGFR VARIANTS ON INTRACRANIAL PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN NSCLC PATIENTS WITH BRAIN METASTASES UNDERGOING STEREOTACTIC RADIOSURGERY
MMOD-05 THE IMPACT OF EGFR VARIANTS ON INTRACRANIAL PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN NSCLC PATIENTS WITH BRAIN METASTASES UNDERGOING STEREOTACTIC RADIOSURGERY Open
Outcomes for patients with brain metastases (BM) from targetable epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) have been improved with tyrosine kinase inhibitors (TKIs). However, outcomes following ster…
View article: RADT-07 IMPACT OF KEAP1/NFE2L2 VARIANTS ON LOCAL CONTROL IN NSCLC BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY
RADT-07 IMPACT OF KEAP1/NFE2L2 VARIANTS ON LOCAL CONTROL IN NSCLC BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY Open
The Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-like 2 (NFE2L2) reactive oxygen species processing pathway may be a useful biomarker of clinical radioresistance in localized non-small cell lung cancer (NSCLC). It…
View article: RADT-04 IMPROVED SURVIVAL IN PATIENTS WITH RADIONECROSIS VS. LOCAL RECURRENCE AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
RADT-04 IMPROVED SURVIVAL IN PATIENTS WITH RADIONECROSIS VS. LOCAL RECURRENCE AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES Open
PURPOSE: Radionecrosis (RN) is a dose-limiting toxicity after stereotactic radiosurgery (SRS) for brain metastases. How RN affects patient outcomes following SRS is not well described. Therefore, we characterized survival outcomes of patie…
View article: Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course
Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course Open
In this cohort study of patients with brain metastases completing SRS, neurologic symptoms at ITCP is prognostic for OS. This data informs post-SRS surveillance in clinical practice as well as future prospective studies needed in the moder…
View article: Impact of <i>TP53</i> mutations on brain metastasis control in non-small cell lung cancer patients undergoing stereotactic radiosurgery.
Impact of <i>TP53</i> mutations on brain metastasis control in non-small cell lung cancer patients undergoing stereotactic radiosurgery. Open
Among NSCLC patients with BMs, the potential association between TP53 status and post-SRS FFLIP warrants further investigation in a larger prospective cohort.
View article: Multi-Institutional Outcomes Following Stereotactic Radiosurgery for Gastrointestinal Brain Metastases
Multi-Institutional Outcomes Following Stereotactic Radiosurgery for Gastrointestinal Brain Metastases Open
View article: Evaluating the Reliability of Chat-GPT Model Responses for Radiation Oncology Patient Inquiries
Evaluating the Reliability of Chat-GPT Model Responses for Radiation Oncology Patient Inquiries Open
View article: LMAP-08 MULTI-INSTITUTIONAL CLINICAL OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM GYNECOLOGIC MALIGNANCIES
LMAP-08 MULTI-INSTITUTIONAL CLINICAL OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM GYNECOLOGIC MALIGNANCIES Open
Brain metastases (BM) are rare in patients with gynecologic (GYN) malignancies. We identified and analyzed all patients who completed a course of stereotactic radiosurgery (SRS) between 1/2015 and 12/2020 across two institutions. Demograph…
View article: CLRM-01 DETERMINANTS OF SYMPTOMATIC INTRACRANIAL PROGRESSION FOLLOWING AN INITIAL STEREOTACTIC RADIOSURGERY COURSE
CLRM-01 DETERMINANTS OF SYMPTOMATIC INTRACRANIAL PROGRESSION FOLLOWING AN INITIAL STEREOTACTIC RADIOSURGERY COURSE Open
To determine the prognostic significance of neurologic symptoms at progression for patients with brain metastases (BM) undergoing stereotactic radiosurgery (SRS), all patients completing an initial course of SRS between 1/2015 and 12/2020 …
View article: Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases
Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases Open
Importance Clinical trials for metastatic malignant neoplasms are increasingly being extended to patients with brain metastases. Despite the preeminence of progression-free survival (PFS) as a primary oncologic end point, the correlation o…
View article: Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Comparisons of CA 19-9 concentration and cfDNA mutant allele fractions in plasma. (A-E) cfDNA mutant allele fractions ("cfDNA percentage") versus CA 19-9 units per milliliter (U/mL) were determined at similar times for five patients with t…
View article: Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Tumor marker levels and cfDNA mutant allele fractions across 19 time intervals for eight patients that were serially monitored via blood draws.
View article: Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Tumor marker levels and cfDNA mutant allele fractions across 19 time intervals for eight patients that were serially monitored via blood draws.
View article: Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Complete patient-level and mutation-level concordance information, mutation identities, and monitoring status for each patient in study.
View article: Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Characteristics of the 26 patients in study.
View article: Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Complete patient-level and mutation-level concordance information, mutation identities, and monitoring status for each patient in study.
View article: Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Characteristics of the 26 patients in study.
View article: Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Comparisons of CA 19-9 concentration and cfDNA mutant allele fractions in plasma. (A-E) cfDNA mutant allele fractions ("cfDNA percentage") versus CA 19-9 units per milliliter (U/mL) were determined at similar times for five patients with t…
View article: Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in…
View article: Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
List of genes and exons captured in the Guardant360 cfDNA sequencing test.
View article: Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
List of genes and exons captured in the Guardant360 cfDNA sequencing test.
View article: Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in…
View article: Data from Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Data from Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors Open
Purpose: The PARP inhibitor (PARPi) talazoparib may potentiate activity of chemotherapy and toxicity in cells vulnerable to DNA damage.Experimental Design: This phase I study evaluated the safety, tolerability, pharmacokineti…